Although the clinical significance of proliferation activity in the subgroups of breast cancer patients has not been well defined [17], CPCC showed a significant correlation with survival, especially in HER2-negative luminal subtype of patients but not in HER2-positive subtype. Here, ERBB2 is linked to breast carcinoma.